Bio-Rad starts roadshow for $200 million 10-year notes via Goldman Sachs

By Paul A. Harris

St. Louis, July 28 - Bio-Rad Laboratories, Inc. started the roadshow Monday for an offering of $200 million senior subordinated notes due 2013 (BB-), according to a syndicate source.

The deal is expected to price during the week of August 4, the source added.

Goldman Sachs & Co. is bookrunner on the Rule 144A/Regulation S offering. Credit Suisse First Boston, Deutsche Bank Securities Inc., Banc One Capital Markets and Robert W. Baird are co-managers.

Proceeds will be used to fund the company's tender for $88.715 million 11 5/8% senior subordinated notes due 2007 and for general corporate purposes.

Bio-Rad is a Hercules, Calif.-based manufacturer and distributor of life science research products and clinical diagnostics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.